Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor.

Pai-Scherf, L H

Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Sep 1999 - 2311-5 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article

1078-0432


ADP Ribose Transferases
Adult
Alanine Transaminase--metabolism
Antibodies, Monoclonal--adverse effects
Antibodies, Neoplasm--biosynthesis
Aspartate Aminotransferases--metabolism
Bacterial Toxins--adverse effects
Breast Neoplasms--drug therapy
Chemical and Drug Induced Liver Injury
Esophageal Neoplasms--drug therapy
Exotoxins--adverse effects
Female
Humans
Immunotoxins--adverse effects
Liver--drug effects
Liver Diseases--enzymology
Male
Middle Aged
Receptor, ErbB-2--metabolism
Recombinant Proteins--adverse effects
Virulence Factors
Pseudomonas aeruginosa Exotoxin A